Can a patient be on both Tresiba (insulin degludec) and Lantus (insulin glargine)?

No, a Patient Should Not Be on Both Tresiba and Lantus Simultaneously

A patient should never be on both Tresiba (insulin degludec) and Lantus (insulin glargine) at the same time, as this represents unnecessary duplication of basal insulin therapy with no clinical benefit and significantly increased risk of hypoglycemia. Both medications serve the identical therapeutic purpose of providing 24-hour basal insulin coverage, and combining them creates dangerous overlap without improving glycemic control 1, 2, 3.

Why This Combination Is Inappropriate

Pharmacologic Redundancy

• Both Tresiba and Lantus are long-acting basal insulin analogs designed to suppress hepatic glucose production and provide continuous background insulin coverage throughout the day 3, 4.
• Tresiba has an ultra-long duration of action exceeding 42 hours, while Lantus provides relatively peakless coverage for up to 24 hours 2, 5.
• Using both simultaneously creates overlapping basal insulin coverage with no additional therapeutic benefit 1, 3.

Increased Hypoglycemia Risk

• The American Diabetes Association explicitly recommends against routinely overlapping two different basal insulins, as this approach creates unnecessary complexity with increased hypoglycemia risk 1.
• Combining two basal insulins dramatically increases the risk of severe hypoglycemia, particularly nocturnal hypoglycemia, without improving HbA1c control 1, 6.
• Clinical trials demonstrate that both Tresiba and Lantus achieve similar glycemic control when used individually, making combination therapy medically unjustified 4.

What Should Be Done Instead

If Basal Insulin Alone Is Insufficient

• When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day with A1C remaining above target, add prandial insulin or a GLP-1 receptor agonist rather than adding a second basal insulin 1, 2, 3.
• Start with 4 units of rapid-acting insulin before the largest meal, or use 10% of the current basal dose 1.
• Consider adding a GLP-1 receptor agonist to basal insulin for potent glucose-lowering with less weight gain and hypoglycemia compared to intensified insulin regimens 1, 2.

Signs of Overbasalization (When to Stop Escalating Basal Insulin)

• Basal insulin dose >0.5 units/kg/day 1.
• Bedtime-to-morning glucose differential ≥50 mg/dL 1.
• Recurrent hypoglycemia episodes 1.
• High glucose variability throughout the day 1.

If Switching Between Basal Insulins

• When converting from Lantus to Tresiba, use a unit-to-unit conversion initially, then titrate based on fasting glucose patterns 2, 3.
• Never overlap the two insulins during the transition period 1.
• Patients experiencing recurrent nocturnal hypoglycemia on Lantus should be switched to Tresiba (not added to it) for its superior hypoglycemia safety profile 2.

Critical Clinical Caveats

Proper Basal-Bolus Regimen Structure

• For type 1 diabetes, approximately 40-60% of total daily insulin should be basal insulin, with the remainder as prandial insulin 1, 3.
• For type 2 diabetes, start with basal insulin alone (10 units or 0.1-0.2 units/kg/day), then add prandial insulin only if needed after optimizing basal doses 1, 3.

When Basal Insulin Needs Are High

• For patients requiring very high basal insulin doses (>200 units/day), use concentrated formulations like U-300 glargine (Toujeo) or U-200 degludec, not two separate basal insulins 3.
• U-300 glargine requires approximately 10-18% higher daily doses compared to U-100 glargine due to modestly lower efficacy per unit 3.

Monitoring Requirements

• Daily fasting blood glucose monitoring is essential when adjusting any basal insulin regimen 1.
• Check pre-meal and 2-hour postprandial glucose to guide prandial insulin adjustments if added 1.
• Reassess every 3 days during active titration and every 3-6 months once stable 1.

Common Pitfalls to Avoid

• Never use two basal insulins simultaneously—this is explicitly condemned by diabetes guidelines 1.
• Never continue escalating a single basal insulin beyond 0.5-1.0 units/kg/day without addressing postprandial hyperglycemia with prandial insulin or GLP-1 RA 1, 2.
• Never delay adding prandial insulin when signs of overbasalization are present 1.
• Always continue metformin (unless contraindicated) when intensifying insulin therapy, as this combination provides superior control with reduced insulin requirements 1.